iPT-141: The best option for sexual enhancement!

CEM Store

CEM Store

Board Sponsor
Awards
1
  • Established
Let's dive deep into iPT-141 (iPT) and why it is an effective tool for research in not just greatly enhancing erections but also overall sexual libido and satisfaction for both male and female test subjects. iPT is a synthetically made peptide, an analogue of the naturally occurring peptide alpha-melanocyte-stimulating hormone (alpha-MSH). iPT is an agonist at melanocortin receptors in the body of which its effects are primarily found in the central nervous system (CNS). Melanocortins have CNS and peripheral roles in a wide variety of bodily functions. The peptide iPT acts in the CNS to promote erections as seen in research with iPT and also possesses enhanced sexual activity beyond just its erectogenic effects. In short to me that means it can have a positive effect in females subjects as well.


Before I dive, too deep, into iPT and its positive qualities let's roll back time a bit to before iPT became reality to see just how it came about. MT2 is a well-known peptide being investigated in its effects on pigmentation formation (tanning) and has been for a while now. Many researchers have heard of this peptide which is also an analogue of alpha-MSH much like iPT. During early research into MT2 and its effects it was found that the administration of this synthetic analog of alpha-MSH (MT2) caused strong penile erections in a variety of species! It is this trait of MT2 that lead the way to the development and synthesis of the iPT, I am writing about today. In a way, iPT was made from MT2! Even in early research the abilities of iPT to induce strong erections and a raise in libido were seen across the board and this only sped up its popularity amongst researchers. This is why melanocortinergic compounds have recently been of very big interest to many researchers.


iPT has been found not only to enhance the male test subjects penile erection and sexual response, but has also has been sound to have sexual enhancing qualities in female subjects as well. This is VERY important to note since currently there is not really any known compound known to enhance female sexual response in any research setting, until now. It is well known that a variety of hormones and neurotransmitter systems are involved in the sexual response of living animals. Some of these include; testosterone, dopamine, serotonin and of course now we can add the melanocortin systems to that list as well. iPT has been shown to have sexual enhancing properties which are thought to be due to the binding of the melanocortin receptors in the central nervous system. The main area found to be effected by iPT research is the area called the hypothalamus. One of the major areas of interest (at least to me) is the fact iPT enhances not only male subject's sexual response but has shown time and time again to greatly enhance the female test subject's sexual response as well. In one study (just as an example) that used a model that; "allows ovariectomized, hormone-primed female rats to control the timing of sexual encounters with males, we tested the ability of iPT to increase appetitive (proceptive) and/or consummatory sexual behaviors. iPT dramatically and selectively increased measures of solicitation in female rats, without altering pacing or lordosis, following both peripheral (subcutaneous) administration or infusions directly into the lateral ventricles or medial preoptic area (mPOA), but not the ventromedial hypothalamus." This study shows what many other current studies are showing, that iPT possesses the behavioral, pharmacological, and neuroanatomical effects that are well suited for further research into possible treatments of hypoactive sexual desire disorders in females as well as males. With female subjects the vascular and non-vascular smooth muscle relaxation in the vagina is very important for sexual arousal and peptides such as iPT have been shown to exert contractile and relaxant effects on vaginal strips and arteries. Findings like these have greatly fueled the research into iPT and other CNS acting agents for their unique positive abilities at helping sexual dysfunction and disorders of that nature in male and female subjects.


CNS stimulation and control of sexual function primarily originates in the region called the hypothalamus, but also include medial preoptic area, and the paraventricular nucleus. iPT also affects the neurotransmitters responsible for sexual function like: serotonin, dopamine, and oxytocin. I feel the role of peptides in arousal has been greatly ignored for a very long time and it is nice to now finally have an effective research compound for this area of research. When researching an area like enhancing sexual response one must look at the interrelationship between sex steroids and neurotransmitters which affect the CNS and genitalia. Hormones are nothing new and if there is a study in which hormones are an issue replacing them is nothing new, but now with hypothalamic neuropeptides such as iPT we can now also centrally modulate sexual arousal making sexual response or dysfunction research much more effective. iPT is possibly one of the first centrally acting compounds to have a worthwhile utility in the research and treatment of sexual dysfunction with a broad test subject base.


Currently available compounds for erectile dysfunction (ED) research share the same mechanism of action and pharmacologic properties. They are all PD5 inhibitors (such as Viagra) and they share the same limitations under some circumstances which leads to sometimes very ineffective research outcomes. With iPT we now have a new avenue/tool to work with in this sort of research. Sexual arousal disorder can affect many species and there are no effective drugs for research in this area since PD5 inhibitors like Viagra just don't do it for this sort of research? until now! iPT researchers have reported back significantly greater intercourse satisfaction than those in the placebo group. This has been seen in various research studies and is commonly seen with iPT research. Administration of the iPT agonist has been shown to be well tolerated during research and not associated the hypotension that has been observed with PD5 inhibitors currently used in erectile dysfunction research. Not only is iPT effective, it has been found to be very safe in research subjects.


That's not to say that PD5 inhibitor research doesn't have its place. There have been studies on iPT and PD5 inhibitors administered together showing that administration of a PD5 inhibitor and iPT to be more effective than just the administration of a PD5 inhibitor alone. It was also found to be safe and well tolerated when used together during research. An iPT and PD5 inhibitor combo may even be an option for researchers that need to administer higher doses of PD5 inhibitor in subjects to have the sought after outcome of the research setting, or in subjects which do not tolerate PD5 inhibitors very well.


The safety and effectiveness of this compound is just amazing and the if fact used alone or in combination with other compounds has been shown effective and safe just warrants why it has grown to be one of the most currently talked about sexual enhancing compounds known to man!


I hope you enjoyed this article and that it has shed some light on iPT's history and what it can do for your research.




Check it out >> iPT-141 10mg - Peptides






Ref:


1) Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro Pharmacological profiling of neuropeptides on... [Br J Pharmacol. 2008] - PubMed - NCBI
2) effects of melanocortins in male sexual dysfunction Preclinical effects of melanocortins in male... [Int J Impot Res. 2008] - PubMed - NCBI
3) centrally acting agents in male sexual dysfunction Clinical applications of centrally acting ag... [Int J Impot Res. 2008] - PubMed - NCBI
4) Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study Salvage of sildenafil failures with bremelanotide: a ... [J Urol. 2008] - PubMed - NCBI
5) Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder Evaluation of the safety and efficacy of bremelano... [J Sex Med. 2008] - PubMed - NCBI
6) Central nervous system-acting agents and the treatment of erectile and sexual dysfunction Central nervous system-acting agents and the t... [Curr Urol Rep. 2007] - PubMed - NCBI
7) Bremelanotide: an overview of preclinical CNS effects on female sexual functionhttp://www.ncbi.nlm.nih.gov/pubmed/17958619
8) Melanocortins in the treatment of male and female sexual dysfunctionhttp://www.ncbi.nlm.nih.gov/pubmed/17584134
9) An effect on the subjective sexual response, sexual arousal disorder, bremelanotide (PT-141), a melanocortin receptor agonisthttp://www.ncbi.nlm.nih.gov/pubmed/16839319
10) low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile responsehttp://www.ncbi.nlm.nih.gov/pubmed/15833522
11) PT-141: a melanocortin agonist for the treatment of sexual dysfunctionhttp://www.ncbi.nlm.nih.gov/pubmed/12851303
12) Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141http://www.ncbi.nlm.nih.gov/pubmed/14999221




iPT-141 10mg - Peptides
 

Similar threads


Top